These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15698520)

  • 1. Increased levels of NF-kappaB inhibitors (IkappaBalpha and IkappaBgamma) in the intestinal mucosa of Crohn's disease patients during infliximab treatment.
    Guidi L; Costanzo M; Ciarniello M; De Vitis I; Pioli C; Gatta L; Pace L; Tricerri A; Bartoloni C; Coppola L; Balistreri P; Doria G; Fedeli G; Gasbarrini GB
    Int J Immunopathol Pharmacol; 2005; 18(1):155-64. PubMed ID: 15698520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal NOD2 expression and NF-kappaB activation in pediatric Crohn's disease.
    Stronati L; Negroni A; Merola P; Pannone V; Borrelli O; Cirulli M; Annese V; Cucchiara S
    Inflamm Bowel Dis; 2008 Mar; 14(3):295-302. PubMed ID: 18092345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease.
    Thiele K; Bierhaus A; Autschbach F; Hofmann M; Stremmel W; Thiele H; Ziegler R; Nawroth PP
    Gut; 1999 Nov; 45(5):693-704. PubMed ID: 10517905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanisms of prednisone inhibition of inflammation in Crohn's disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression.
    Wild GE; Waschke KA; Bitton A; Thomson AB
    Aliment Pharmacol Ther; 2003 Aug; 18(3):309-17. PubMed ID: 12895215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis.
    Visekruna A; Joeris T; Seidel D; Kroesen A; Loddenkemper C; Zeitz M; Kaufmann SH; Schmidt-Ullrich R; Steinhoff U
    J Clin Invest; 2006 Dec; 116(12):3195-203. PubMed ID: 17124531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
    Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
    Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease.
    Segain JP; Raingeard de la Blétière D; Bourreille A; Leray V; Gervois N; Rosales C; Ferrier L; Bonnet C; Blottière HM; Galmiche JP
    Gut; 2000 Sep; 47(3):397-403. PubMed ID: 10940278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enalapril inhibits nuclear factor-κB signaling in intestinal epithelial cells and peritoneal macrophages and attenuates experimental colitis in mice.
    Lee C; Chun J; Hwang SW; Kang SJ; Im JP; Kim JS
    Life Sci; 2014 Jan; 95(1):29-39. PubMed ID: 24239644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
    Noth R; Stüber E; Häsler R; Nikolaus S; Kühbacher T; Hampe J; Bewig B; Schreiber S; Arlt A
    J Crohns Colitis; 2012 May; 6(4):464-9. PubMed ID: 22398062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease.
    Ferkolj I; Ihan A; Markovic S
    Hepatogastroenterology; 2005; 52(64):1128-33. PubMed ID: 16001645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide inhibits adhesion molecule expression in activated human colon serosal fibroblasts by preventing NF-kappaB activation.
    Tao Q; Ren J; Li J
    J Surg Res; 2007 Jun; 140(1):84-9. PubMed ID: 17275031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-inflammatory Effects of Ganoderma lucidum Triterpenoid in Human Crohn's Disease Associated with Downregulation of NF-κB Signaling.
    Liu C; Dunkin D; Lai J; Song Y; Ceballos C; Benkov K; Li XM
    Inflamm Bowel Dis; 2015 Aug; 21(8):1918-25. PubMed ID: 25993687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy.
    Schmidt C; Giese T; Hermann E; Zeuzem S; Meuer SC; Stallmach A
    Inflamm Bowel Dis; 2007 Jan; 13(1):65-70. PubMed ID: 17206641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease.
    Agnholt J; Dahlerup JF; Buntzen S; Tøttrup A; Nielsen SL; Lundorf E
    Aliment Pharmacol Ther; 2003 Mar; 17(5):703-10. PubMed ID: 12641520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Vitamin D analogue TX 527 blocks NF-kappaB activation in peripheral blood mononuclear cells of patients with Crohn's disease.
    Stio M; Martinesi M; Bruni S; Treves C; Mathieu C; Verstuyf A; d'Albasio G; Bagnoli S; Bonanomi AG
    J Steroid Biochem Mol Biol; 2007 Jan; 103(1):51-60. PubMed ID: 17049230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased nuclear factor-kappaB activation in peripheral blood monocytes of patients with rheumatoid arthritis is mediated primarily by tumor necrosis factor-alpha.
    Dichamp I; Bourgeois A; Dirand C; Herbein G; Wendling D
    J Rheumatol; 2007 Oct; 34(10):1976-83. PubMed ID: 17896809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment.
    Ljung T; Axelsson LG; Herulf M; Lundberg JO; Hellström PM
    Aliment Pharmacol Ther; 2007 Apr; 25(8):925-32. PubMed ID: 17402996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.
    ten Hove T; van Montfrans C; Peppelenbosch MP; van Deventer SJ
    Gut; 2002 Feb; 50(2):206-11. PubMed ID: 11788561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.